INSPYR THERAPEUTICS INC (OTCMKTS:NSPX) had a decrease of its shares shorted by 92.59%. It was announced in January by FINRA the 3,800 shares shorted on NSPX. The 51,300 previous shares are down with 92.59%.

The stock decreased 6.90% or $0.0002 during the last trading session, reaching $0.0027.Inspyr Therapeutics, Inc. has volume of 2.89M shares. Since January 23, 2018 NSPX has 0.00% and is . The stock the S&P500 by 0.00%.

Inspyr Therapeutics, Inc., an early-stage pharmaceutical company, focuses on the discovery and development of prodrug cancer therapeutics in the United States.The firm is valued at $330,247. It develops cancer therapeutics for the treatment of solid tumors, including brain, liver, prostate, and other cancers.Last it reported negative earnings. The company's lead drug candidate is mipsagargin, which has completed an open label single arm Phase II clinical trial in patients with advanced hepatocellular carcinoma or liver cancer.